We've started preparing for the BIO convention in Philadelphia in June. Preparing? Already? Yes. Why start now? We'll give you three reasons: New Partnering Interface - BIO has unveiled a…
Are you an independent consultant? Are you looking for a new platform or channel to help grow and expand your practice? Why not join us! Lacerta Bio is looking…
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China.…
These past few weeks I have noticed how negative and bimodal we have become when clinical results are announced. More and more, Phase II and III results are labeled #FAIL…
I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped…
From a consulting perspective, here is how we view business development, using the acronym LUNCH: Learn what the client wants: What is the objective? Is it cash now in the…
There is a terrific article in Nature Biotechnology entitled Keys to the Kingdom. The article discusses a number of issues bioentrepreneurs may encounter when trying to license technology from a…
Today's issue of Institutional Investor has an interesting article on the reality of 10-year venture funds. The author presents statistics demonstrating that <10% of ten-year venture funds actually liquidate…
Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by…